EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseOpen Access · CC BY-NC 4.0

Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials

Scott M Friedman, Yingxin Xu, Steven Sherman, Andreas Kuznik, Ali Mojebi, Sam Keeping, Keith Chan, Theodore Leng, Nimesh Patel

Ophthalmology and Therapy · 2025-11 · 14 (11) · 2919-2936

DOI: 10.1007/s40123-025-01247-3 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift Ophthalmology and Therapy, online erschienen am 25.09.2025. Verfasst von Scott M Friedman und 8 weiteren Autor:innen. Beteiligte Einrichtung: Florida Retina Consultants, Lakeland, FL, USA. smfriedman83@hotmail.com. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Regeneron Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Reducing intravitreal injection frequency while maintaining efficacy is a critical goal in alleviating the burden associated with anti-vascular endothelial growth factor (VEGF) therapy in patients with diabetic macular edema (DME) or neovascular age-related macular degeneration (nAMD). In clinical trials, aflibercept 8 mg and faricimab 6 mg administered at extended dosing intervals have demonstrated similar efficacy compared with aflibercept 2 mg, but with fewer injections. This network meta-analysis (NMA) indirectly compared numbers of injections and efficacy between aflibercept 8 mg and faricimab 6 mg administered according to a treat-and-extend (T&E)-based regimen in patients with DME or nAMD. METHODS: A systematic literature review was conducted on 10 January 2025, to identify randomized controlled trials of aflibercept 8 mg or faricimab T&E with observation periods of approximately 2 years. Outcomes included number of injections, absolute change from baseline in best-corrected visual acuity (BCVA), and absolute and percentage change from baseline in central subfield thickness (CST). NMAs were performed with Bayesian statistical models. Injection numbers were adjusted to 104 weeks to account for differences in trial observation periods. RESULTS: The NMA included 2-year data from six trials: PHOTON, YOSEMITE, and RHINE (DME); and PULSAR, TENAYA, and LUCERNE (nAMD). Treatment with aflibercept 8 mg was associated with significantly fewer injections compared with faricimab T&E in patients with DME (mean difference -3.62 [95% credible interval -4.22, -3.02]) or nAMD (-1.47 [-1.90, -1.05]). Mean changes from baseline in BCVA (absolute) or CST (absolute and percentage) did not differ significantly between the two treatments. CONCLUSION: This NMA indicated that aflibercept 8 mg required significantly fewer injections while maintaining similar efficacy over 2 years of treatment compared with faricimab T&E in patients with DME or nAMD.

Schlagwörter

Stichwörter der Autor:innen

AfliberceptAnti-VEGF therapyDiabetic macular edemaEfficacyFaricimabIntravitreal injectionNeovascular age-related macular degenerationNetwork meta-analysisSystematic literature review

Autor:innen und Institutionen

  • Florida Retina Consultants, Lakeland, FL, USA. smfriedman83@hotmail.com.
  • Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Precision AQ, Vancouver, BC, Canada.
  • Byers Eye Institute at Stanford University, Stanford University School of Medicine, Palo Alto, CA, USA.
  • Harvard Medical School, Boston, MA, USA.
  • Massachusetts Eye and Ear and Massachusetts General Hospital, Boston, MA, USA.

Förderung

  • Regeneron Pharmaceuticals

Zitieren

APA

Friedman, S. M., Xu, Y., Sherman, S., Kuznik, A., Mojebi, A., Keeping, S., Chan, K., Leng, T., & Patel, N. (2025). Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials. Ophthalmology and Therapy, 14(11), 2919-2936. https://doi.org/10.1007/s40123-025-01247-3

Vancouver

Friedman SM, Xu Y, Sherman S, Kuznik A, Mojebi A, Keeping S, et al. Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials. Ophthalmology and Therapy. 2025;14(11):2919-2936. doi:10.1007/s40123-025-01247-3

BibTeX
@article{Friedman2025,
  author = {Friedman, Scott M and Xu, Yingxin and Sherman, Steven and Kuznik, Andreas and Mojebi, Ali and Keeping, Sam and Chan, Keith and Leng, Theodore and Patel, Nimesh},
  title = {Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials},
  journal = {Ophthalmology and Therapy},
  year = {2025},
  volume = {14},
  number = {11},
  pages = {2919--2936},
  doi = {10.1007/s40123-025-01247-3}
}
Kostenlos starten →